IBI354 Clinical Trials
3 recruitingDrug
Phase 32Phase 11Phase 21
Showing 1–3 of 3 trials
Recruiting
Phase 3
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
HER2-positive Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.540 enrolled1 locationNCT07377643
Recruiting
Phase 3
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube CancerPrimary PeritonealOvarian
Innovent Biologics (Suzhou) Co. Ltd.450 enrolled1 locationNCT06834672
Recruiting
Phase 1Phase 2
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.368 enrolled6 locationsNCT05636215